DOCS Stock Soars: Doximity AI Outperforms Anthropic

Shares of Doximity, trading as DOCS, surged in pre-market trade after its CEO stated the company's clinical AI outperformed Anthropic's model. CEO Jeff Tangney reported Doximity's AI had a 4.8% error rate, significantly lower than Anthropic's Fable 5, which recorded 13.6%. What's interesting is that this performance is attributed to proprietary medical data and physician oversight. Following this news, both Canaccord and BMO Capital raised their price targets for Doximity stock. Canaccord now forecasts AI revenue will become a meaningful growth driver in the third quarter, especially with demand from pharmaceutical companies. The stock more than tripled at one point, putting it on track for a six-month high. This indicates a strong market reaction to the company's advancements in AI.